Core Viewpoint - Hansoh Pharmaceutical Group Co., Ltd. has entered into an exclusive licensing, collaboration, and distribution agreement with Glenmark Specialty S.A. for Amivantamab, a third-generation EGFR-TKI for non-small cell lung cancer (NSCLC) [1] Group 1: Agreement Details - The agreement grants Glenmark exclusive rights to develop and commercialize Amivantamab in specified regions including the Middle East, Africa, Southeast Asia, South Asia, Australia, New Zealand, Russia, and certain Caribbean countries [1] - Hansoh Pharmaceutical will receive an upfront payment along with potential milestone payments exceeding $1 billion, as well as tiered royalties on net sales within the licensed regions [1]

Group 1 - China Petroleum & Chemical Corporation (Sinopec) launched a special action to enhance the market value of its listed companies during an investor communication event held on December 16 [1] - The action aims to improve investment value and increase shareholder returns through three main aspects: enhancing governance efficiency, improving the return system, and optimizing capital layout [1][2] - The governance efficiency will focus on management enhancement, strategic development planning, capital operation, and talent development in the capital market [1] - The return system will emphasize quality information disclosure, investor relations management, and a stable cash dividend policy, along with share buybacks to enhance shareholder returns [1] - The capital layout optimization will involve mergers and acquisitions, equity financing, and adjustments to the industrial layout to enhance the overall market value of listed companies during the 14th Five-Year Plan period [1] Group 2 - The event included executives from nine listed companies under Sinopec, as well as representatives from state-owned securities regulatory agencies, central enterprises, and financial institutions [2] Group 3 - The U.S. stock market saw the Dow Jones Industrial Average and S&P 500 decline for three consecutive days, while large tech stocks mostly rose [3] - The Dow Jones fell by 302.3 points to close at 48,114.26, a decrease of 0.62%, and the S&P 500 dropped by 16.25 points to 6,800.26, a decline of 0.24% [3] - The Nasdaq Composite Index increased by 54.05 points to 23,111.46, a rise of 0.23%, with Tesla reaching a historic high [3] Group 4 - The European Union is preparing to propose easing emissions regulations for new cars, effectively abolishing the ban on internal combustion engines, allowing manufacturers to slow down the rollout of electric vehicles [4] - This move aligns the EU's policies more closely with the U.S., where former President Trump is rolling back automotive efficiency standards [4] - Ford has announced a $19.5 billion charge related to its electric vehicle business overhaul due to the profitability challenges faced by global automakers [4] Group 5 - The Ministry of Commerce of China announced that starting December 17, 2025, anti-dumping duties will be imposed on imported pork and pork products from the EU for a period of five years [5] - The anti-dumping duties will be calculated based on the customs-determined taxable price of the imported goods [5] Group 6 - China Energy Engineering Corporation announced that the first phase of the world's largest green hydrogen and ammonia integrated project, the Zhongnengjian Songyuan Hydrogen Energy Industrial Park, has officially commenced operations [6][7] Group 7 - Kangfeng Biotechnology received approval from the National Medical Products Administration for its anti-reflux system, enhancing the diversity of its product portfolio [8] Group 8 - Hansoh Pharmaceutical entered into a licensing agreement with Glenmark for the commercialization of Amivantamab, a treatment for non-small cell lung cancer [9] - The agreement includes upfront payments and potential milestone payments exceeding $1 billion, along with tiered royalties on net sales in the licensed regions [9] Group 9 - Shandong High Holding signed an EPC contract for a wind farm project in Guangxi, marking its active integration into the clean energy sector [10] Group 10 - MMG Australia Limited and Minmetals North-Europe signed a sales agreement for Rosebery concentrate, covering 100% of production for 2026 and 2027, with an expected annual output of approximately 6,000 dry metric tons [11] Group 11 - China General Nuclear Power Corporation announced the commencement of full construction for the Ningde Unit 6 nuclear reactor, marking a significant milestone in its development [12] Group 12 - Daqi Pharmaceutical received approval in Malaysia for its drug Selinexor to treat relapsed or refractory diffuse large B-cell lymphoma in adult patients [13] Group 13 - CIMC Enric's first large-scale biomass methanol project in Guangdong officially commenced production, with an expected annual capacity of 50,000 tons [14] - The project aims to achieve full operational capacity before the 2026 Spring Festival, contributing significantly to revenue [14][15] - The company is also exploring a second phase of the project, with plans for an annual output of 200,000 tons by 2027 [15]

【重大事项】 HASHKEY HLDGS(03887)香港公开发售获393.71倍认购 每股发售价6.68港元 【回购增减持】 腾讯控股(00700)12月16日耗资约6.36亿港元回购106.7万股 小米集团-W(01810)12月16日斥资2.94亿港元回购720万股 快手-W(01024)12月16日斥资1.16亿港元回购182.31万股 吉利汽车(00175)12月16日斥资5054.44万港元回购29.99万股 碧桂园服务(06098)12月16日耗资约3127.38万港元回购500万股 中远海控(01919)12月16日斥资4031.69万港元回购300万股 歌礼制药-B(01672)将股份购回资金由最多3亿港元增至最多5亿港元 红星美凯龙(01528)股东淘宝控股及新零售基金合计减持公司4164.66万股H股 金风科技(02208)股东和谐健康累计减持约3594.99万股股份 世纪联合控股(01959)控股权易主 获折让约66.78%提全购要约 12月17日复牌 【财报数据】 中国太保(02601)：太平洋人寿保险前11个月原保险保费收入为2503.22亿元 同比增长9.4% 中煤能源(0189 ...

来源：视频滚动新闻 翰森制药(03692.HK)在港交所公告，于二零二五年十二月十六日，本公司全资附属公司江苏豪森药业集 团有限公司与Glenmark Specialty S.A.就阿美替尼订立独家许可、合作及分销协议。阿美替尼是一款用于 治疗非小细胞肺癌的三代表皮生长因子受体-酪氨酸激酶抑制剂。根据许可协议，许可人将授予被许可 人独占许可，允许其在授权区域开发并商业化阿美替尼。 ...

中国能源建设(03996.HK)：投资建设的中能建松原氢能产业园(绿色氢氨醇一体化)项目一期工程正式投产运行。 中煤能源(01898.HK)：前11月商品煤销量为约2.34亿吨，同比减少8.7%。11月煤销量为2174万吨，同比减少15.7%。 中国太保(02601.HK)：前11月，太平洋人寿累计原保险保费收入为人民币2503.22亿元，同比增长9.4%，太平洋财险累计原保险保费收入为人民币1876.82亿 元，同比增长0.3%。 中国铁建(01186.HK)：拟发行不超过40亿元可续期公司债券。 智通财经12月16日讯（编辑 冯轶）智通财经为您带来今日港股重要公告 2）回购动态 1）公司要闻 翰森制药(03692.HK)：与GLENMARK就阿美替尼订立许可协议。 公告称，根据协议将获得首付款和后续可能累计超过十亿美元的监管和商业里程碑付款，以及授权区域内净销售额的分级特许权使用费。 越秀地产(00123.HK)：获授5亿港元的定期贷款融资。 腾讯控股(00700.HK)：斥资约6.36亿港元回购106.7万股，回购价592.5-602.5港元。 小米集团-W(01810.HK)：斥资2.94亿港元回购7 ...

翰森制药(03692)发布公告，于2025年12月16日，公司全资附属公司江苏豪森药业集团有限公司(许可人) 与Glenmark Specialty S.A.(被许可人)就阿美替尼订立独家许可、合作及分销协议(许可协议)。阿美替尼 是一款用于治疗非小细胞肺癌(NSCLC)的三代表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)。 根据许可协议，许可人将授予被许可人独占许可，允许其在授权区域(中东与非洲、东南亚与南亚、澳 大利亚、新西兰、俄罗斯与其他独联体国家，以及协议覆盖的部分特定加勒比国家)开发并商业化阿美 替尼。许可人将获得首付款和后续可能累计超过十亿美元的监管和商业里程碑付款，以及授权区域内净 销售额的分级特许权使用费。 ...

根据许可协议，许可人将授予被许可人独占许可，允许其在授权区域(中东与非洲、东南亚与南亚、澳 大利亚、新西兰、俄罗斯与其他独联体国家，以及协议覆盖的部分特定加勒比国家)开发并商业化阿美 替尼。许可人将获得首付款和后续可能累计超过十亿美元的监管和商业里程碑付款，以及授权区域内净 销售额的分级特许权使用费。 格隆汇12月16日丨翰森制药(03692.HK)宣布，于2025年12月16日，公司全资附属公司江苏豪森药业集团 有限公司(「许可人」)与Glenmark SpecialtyS.A.(「被许可人」)就阿美替尼订立独家许可、合作及分销 协议(「许可协议」)。阿美替尼是一款用于治疗非小细胞肺癌(「NSCLC」)的三代表皮生长因子受体－ 酪氨酸激酶抑制剂(「EGFR-TKI」)。 ...

根据许可协议，许可人将授予被许可人独占许可，允许其在授权区域(中东与非洲、东南亚与南亚、澳 大利亚、新西兰、俄罗斯与其他独联体国家，以及协议覆盖的部分特定加勒比国家)开发并商业化阿美 替尼。许可人将获得首付款和后续可能累计超过十亿美元的监管和商业里程碑付款，以及授权区域内净 销售额的分级特许权使用费。 智通财经APP讯，翰森制药(03692)发布公告，于2025年12月16日，公司全资附属公司江苏豪森药业集团 有限公司(许可人)与Glenmark Specialty S.A.(被许可人)就阿美替尼订立独家许可、合作及分销协议(许可 协议)。阿美替尼是一款用于治疗非小细胞肺癌(NSCLC)的三代表皮生长因子受体-酪氨酸激酶抑制剂 (EGFR-TKI)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 自願公告 與GLENMARK訂立許可協議 翰森製藥集團有限公司（「本公司」）董事會（「董事會」）欣然宣佈，於二零二五年十 二月十六日（交易時段後），本公司全資附屬公司江蘇豪森藥業集團有限公司（「許 可人」）與Glenmark Specialty S.A.（「被許可人」）就阿美替尼訂立獨家許可、合作 及分銷協議（「許可協議」）。阿美替尼是一款用於治療非小細胞肺癌（「NSCLC」） 的三代表皮生長因子受體－酪氨酸激酶抑制劑（「EGFR-TKI」）。 根據許可協議，許可人將授予被許可人獨佔許可，允許其在授權區域（中東與非 洲、東南亞與南亞、澳大利亞、新西蘭、俄羅斯與其他獨聯體國家，以及協議覆 蓋的部分特定加勒比國家）開發並商業化阿美替尼。許可人 ...

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.91% on December 16, with a trading volume of 1.078 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 15, 2024, the fund's total shares reached 10.425 billion, with a total size of 8.174 billion yuan, reflecting a significant increase in shares and size compared to the previous year [1] Fund Performance - The fund manager, Ma Jun, has achieved a return of 64.28% since taking over management on January 3, 2024 [2] - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] Holdings Overview - Major holdings in the fund include: - BeiGene (10.62% holding, market value 817 million yuan) - CanSino Biologics (10.55% holding, market value 812 million yuan) - Innovent Biologics (10.21% holding, market value 786 million yuan) - China National Pharmaceutical Group (9.62% holding, market value 741 million yuan) - CSPC Pharmaceutical Group (7.56% holding, market value 583 million yuan) [2]